(An Autonomous Body Recognized by Ministry of Commerce & Industry, Government of India)
GRI Bio Reports Positive Interim Safety Data for IPF Therapy
GRI Bio shared six-week interim safety results from its Phase IIa trial of GRI-0621, a RAR-βÉŁ dual agonist for idiopathic pulmonary fibrosis (IPF). The oral 4.5mg dose was well tolerated in the first 24 patients, with no adverse effects related to hyperlipidaemia and no significant changes in LDL, HDL, or triglyceride levels. Based on these findings, the interim analysis committee recommended the trial proceed as planned.
The double-blind, placebo-controlled study aims to enroll 36 participants, randomized 2:1 to receive GRI-0621 or placebo. The primary focus is on safety and tolerability over 12 weeks, with secondary endpoints including biomarker shifts, pharmacokinetics, and iNKT cell inhibition. A sub-study will assess NKT cells in lung fluid. Six-week biomarker data is expected in July, with topline results in Q3. Findings align with past safety data from oral tazarotene trials.
01-07-2025
đź“° Recent News
- GRI Bio Reports Positive Interim Safety Data for IPF Therapy
- INmune Bio Alzheimer’s Drug Misses Trial Goals, Stock Plummets
- J&J Reports Promising Antibody Combo Results in Multiple Myeloma Trial
- Amgen and Zai Lab’s Gastric Cancer Trial Hits Survival Goal
- Parkinson’s Drug Shows Promise for Treatment-Resistant Depression
- Genmab Reports Strong Phase Ib/II Results for Epcoritamab Combo in r/r DLBCL
- Astria Reports Positive Interim Data for Navenibart in HAE Trial
- Ventyx Reports Positive Phase IIa Results for Parkinson’s Drug VTX3232
- AbbVie’s Atogepant Outperforms Topiramate in Phase III Migraine Study
- Galderma Reports Promising Long-Term Data for Prurigo Nodularis Treatment